NCT02005744View on ClinicalTrials.gov

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Liver Dysfunction
Interventions
DRUG

CKD-501

CKD-501 0.5mg, PO(per oral), once

Trial Locations (1)

Unknown

Yonsei University Severance Hospital, Soeul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY